Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：841頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014’, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014’, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 8
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview 9
Therapeutics Development 10
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Development by Companies 12
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 23
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Products Glance 26
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Development by Companies 30
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Investigation by Universities/Institutes 43
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development 45
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment 171
Drug Profiles 194
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Recent Pipeline Updates 580
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 802
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 804
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 805
Appendix 815
List of Tables
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2014 35
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H1 2014 36
Number of Products under Development by Companies, H1 2014 38
Number of Products under Development by Companies, H1 2014 (Contd..1) 39
Number of Products under Development by Companies, H1 2014 (Contd..2) 40
Number of Products under Development by Companies, H1 2014 (Contd..3) 41
Number of Products under Development by Companies, H1 2014 (Contd..4) 42
Number of Products under Development by Companies, H1 2014 (Contd..5) 43
Number of Products under Development by Companies, H1 2014 (Contd..6) 44
Number of Products under Development by Companies, H1 2014 (Contd..7) 45
Number of Products under Development by Companies, H1 2014 (Contd..8) 46
Number of Products under Development by Companies, H1 2014 (Contd..9) 47
Number of Products under Investigation by Universities/Institutes, H1 2014 49
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 50
Comparative Analysis by Late Stage Development, H1 2014 51
Comparative Analysis by Clinical Stage Development, H1 2014 52
Comparative Analysis by Early Stage Development, H1 2014 53
Comparative Analysis by Unknown Stage Development, H1 2014 54
Products under Development by Companies, H1 2014 55
Products under Development by Companies, H1 2014 (Contd..1) 56
Products under Development by Companies, H1 2014 (Contd..2) 57
Products under Development by Companies, H1 2014 (Contd..3) 58
Products under Development by Companies, H1 2014 (Contd..4) 59
Products under Development by Companies, H1 2014 (Contd..5) 60
Products under Development by Companies, H1 2014 (Contd..6) 61
Products under Development by Companies, H1 2014 (Contd..7) 62
Products under Development by Companies, H1 2014 (Contd..8) 63
Products under Development by Companies, H1 2014 (Contd..9) 64
Products under Development by Companies, H1 2014 (Contd..10) 65
Products under Development by Companies, H1 2014 (Contd..11) 66
Products under Development by Companies, H1 2014 (Contd..12) 67
Products under Investigation by Universities/Institutes, H1 2014 68
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 69
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2014 70
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genzyme Corporation, H1 2014 71
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Johnson & Johnson, H1 2014 72
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H1 2014 73
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 74
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc., H1 2014 75
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sanofi, H1 2014 76
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca PLC, H1 2014 77
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eli Lilly and Company, H1 2014 78
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlaxoSmithKline plc, H1 2014 79
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H1 2014 80
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genentech, Inc., H1 2014 81
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by medac GmbH, H1 2014 82
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck & Co., Inc., H1 2014 83
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gamida Cell Ltd., H1 2014 84
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Generex Biotechnology Corporation, H1 2014 85
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Plexxikon Inc., H1 2014 86
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioLineRx, Ltd., H1 2014 87
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MediGene AG, Ltd., H1 2014 88
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H1 2014 89
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Egenix, Inc., H1 2014 90
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 91
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Novartis AG, H1 2014 92
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioMarin Pharmaceutical Inc., H1 2014 93
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eisai Co., Ltd., H1 2014 94
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pfizer Inc., H1 2014 95
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2014 96
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 97
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 98
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cell Therapeutics, Inc., H1 2014 99
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals Inc., H1 2014 100
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celgene Corporation, H1 2014 101
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 102
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Incyte Corporation., H1 2014 103
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck KGaA., H1 2014 104
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H1 2014 105
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreMed, Inc., H1 2014 106
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celldex Therapeutics, Inc., H1 2014 107
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immunomedics, Inc., H1 2014 108
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2014 109
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Lorus Therapeutics Inc., H1 2014 110
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MEI Pharma, Inc., H1 2014 111
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OXiGENE, Inc., H1 2014 112
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Critical Outcome Technologies Inc., H1 2014 113
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Topotarget A/S, H1 2014 114
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Xenetic Biosciences plc, H1 2014 115
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by JW Pharmaceutical Corporation, H1 2014 116
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Resverlogix Corp., H1 2014 117
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 118
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Synta Pharmaceuticals Corp., H1 2014 119
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioAlliance Pharma SA, H1 2014 120
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sareum Holdings plc, H1 2014 121
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Innate Pharma SA, H1 2014 122
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oscotec Inc., H1 2014 123
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Stem Cell Therapeutics Corp., H1 2014 124
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellerant Therapeutics, Inc., H1 2014 125
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express, Inc., H1 2014 126
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Chroma Therapeutics Ltd., H1 2014 127
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Colby Pharmaceutical Company, H1 2014 128
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ambit Biosciences Corporation, H1 2014 129
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 130
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Philogen S.p.A., H1 2014 131
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oxford BioTherapeutics Ltd, H1 2014 132
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioMAS Ltd., H1 2014 133
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oncodesign SA, H1 2014 134
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ERYtech Pharma, H1 2014 135
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celator Pharmaceuticals, Inc., H1 2014 136
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corporation., H1 2014 137
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascenta Therapeutics, Inc., H1 2014 138
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Coronado Biosciences, Inc., H1 2014 139
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals, Inc., H1 2014 140
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MacroGenics, Inc., H1 2014 141
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arno Therapeutics, Inc., H1 2014 142
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by TetraLogic Pharmaceuticals., H1 2014 143
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Spirogen Ltd., H1 2014 144
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem, H1 2014 145
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Stemline Therapeutics, Inc., H1 2014 146
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories, LLC, H1 2014 147
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onconova Therapeutics, Inc., H1 2014 148
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kainos Medicine, Inc., H1 2014 149
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Syndax Pharmaceuticals, Inc., H1 2014 150
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2014 151
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Esperance Pharmaceuticals, Inc., H1 2014 152
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Trillium Therapeutics Inc., H1 2014 153
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SBI Biotech Co., Ltd., H1 2014 154
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2014 155
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellceutix Corporation, H1 2014 156
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kiadis Pharma B.V., H1 2014 157
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2014 158
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 159
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science, H1 2014 160
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea AB, H1 2014 161
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kinex Pharmaceuticals, LLC, H1 2014 162
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoImmune, Inc., H1 2014 163
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CureTech Ltd., H1 2014 164
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlycoMimetics, Inc., H1 2014 165
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Janssen Biotech, Inc., H1 2014 166
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merus B.V., H1 2014 167
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics B.V., H1 2014 168
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantex Pharmaceuticals, Inc., H1 2014 169
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2014 170
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Interprotein Corporation, H1 2014 171
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EpiZyme, Inc., H1 2014 172
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Targa Therapeutics Corp., H1 2014 173
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NuCana BioMed Limited, H1 2014 174
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sentinel Oncology Limited, H1 2014 175
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 176
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genosco, H1 2014 177
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BerGenBio AS, H1 2014 178
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advancell., H1 2014 179
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Igenica, Inc., H1 2014 180
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Selvita S.A, H1 2014 181
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 182
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreChem, S.L., H1 2014 183
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AROG Pharmaceuticals LLC, H1 2014 184
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 185
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunGene, Inc., H1 2014 186
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Conkwest, Inc., H1 2014 187
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantargia AB, H1 2014 188
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 189
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H1 2014 190
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 191
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc., H1 2014 192
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SpectraMab GmbH, H1 2014 193
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmedartis GmbH, H1 2014 194
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SYNIMMUNE GmbH, H1 2014 195
Assessment by Monotherapy Products, H1 2014 196
Assessment by Combination Products, H1 2014 197
Number of Products by Stage and Target, H1 2014 200
Number of Products by Stage and Mechanism of Action, H1 2014 207
Number of Products by Stage and Route of Administration, H1 2014 215
Number of Products by Stage and Molecule Type, H1 2014 218
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics - Recent Pipeline Updates, H1 2014 605
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2014 828
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H1 2014 830
List of Figures
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2014 35
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H1 2014 36
Number of Products under Development by Companies, H1 2014 37
Number of Products under Investigation by Universities/Institutes, H1 2014 48
Comparative Analysis by Clinical Stage Development, H1 2014 52
Comparative Analysis by Early Stage Products, H1 2014 53
Comparative Analysis by Unknown Stage Development, H1 2014 54
Assessment by Monotherapy Products, H1 2014 196
Assessment by Combination Products, H1 2014 197
Number of Products by Top 10 Target, H1 2014 198
Number of Products by Stage and Top 10 Target, H1 2014 199
Number of Products by Top 10 Mechanism of Action, H1 2014 205
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 206
Number of Products by Top 10 Route of Administration, H1 2014 213
Number of Products by Stage and Top 10 Route of Administration, H1 2014 214
Number of Products by Top 10 Molecule Type, H1 2014 216
Number of Products by Stage and Top 10 Molecule Type, H1 2014 217
Table of Contents 2
Introduction 8
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview 9
Therapeutics Development 10
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Development by Companies 12
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 23
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Products Glance 26
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Development by Companies 30
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Investigation by Universities/Institutes 43
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development 45
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment 171
Drug Profiles 194
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Recent Pipeline Updates 580
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 802
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 804
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 805
Appendix 815
List of Tables
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2014 35
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H1 2014 36
Number of Products under Development by Companies, H1 2014 38
Number of Products under Development by Companies, H1 2014 (Contd..1) 39
Number of Products under Development by Companies, H1 2014 (Contd..2) 40
Number of Products under Development by Companies, H1 2014 (Contd..3) 41
Number of Products under Development by Companies, H1 2014 (Contd..4) 42
Number of Products under Development by Companies, H1 2014 (Contd..5) 43
Number of Products under Development by Companies, H1 2014 (Contd..6) 44
Number of Products under Development by Companies, H1 2014 (Contd..7) 45
Number of Products under Development by Companies, H1 2014 (Contd..8) 46
Number of Products under Development by Companies, H1 2014 (Contd..9) 47
Number of Products under Investigation by Universities/Institutes, H1 2014 49
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 50
Comparative Analysis by Late Stage Development, H1 2014 51
Comparative Analysis by Clinical Stage Development, H1 2014 52
Comparative Analysis by Early Stage Development, H1 2014 53
Comparative Analysis by Unknown Stage Development, H1 2014 54
Products under Development by Companies, H1 2014 55
Products under Development by Companies, H1 2014 (Contd..1) 56
Products under Development by Companies, H1 2014 (Contd..2) 57
Products under Development by Companies, H1 2014 (Contd..3) 58
Products under Development by Companies, H1 2014 (Contd..4) 59
Products under Development by Companies, H1 2014 (Contd..5) 60
Products under Development by Companies, H1 2014 (Contd..6) 61
Products under Development by Companies, H1 2014 (Contd..7) 62
Products under Development by Companies, H1 2014 (Contd..8) 63
Products under Development by Companies, H1 2014 (Contd..9) 64
Products under Development by Companies, H1 2014 (Contd..10) 65
Products under Development by Companies, H1 2014 (Contd..11) 66
Products under Development by Companies, H1 2014 (Contd..12) 67
Products under Investigation by Universities/Institutes, H1 2014 68
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 69
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2014 70
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genzyme Corporation, H1 2014 71
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Johnson & Johnson, H1 2014 72
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H1 2014 73
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 74
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc., H1 2014 75
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sanofi, H1 2014 76
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca PLC, H1 2014 77
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eli Lilly and Company, H1 2014 78
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlaxoSmithKline plc, H1 2014 79
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H1 2014 80
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genentech, Inc., H1 2014 81
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by medac GmbH, H1 2014 82
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck & Co., Inc., H1 2014 83
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gamida Cell Ltd., H1 2014 84
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Generex Biotechnology Corporation, H1 2014 85
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Plexxikon Inc., H1 2014 86
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioLineRx, Ltd., H1 2014 87
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MediGene AG, Ltd., H1 2014 88
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H1 2014 89
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Egenix, Inc., H1 2014 90
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 91
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Novartis AG, H1 2014 92
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioMarin Pharmaceutical Inc., H1 2014 93
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eisai Co., Ltd., H1 2014 94
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pfizer Inc., H1 2014 95
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2014 96
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 97
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 98
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cell Therapeutics, Inc., H1 2014 99
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals Inc., H1 2014 100
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celgene Corporation, H1 2014 101
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 102
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Incyte Corporation., H1 2014 103
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck KGaA., H1 2014 104
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H1 2014 105
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreMed, Inc., H1 2014 106
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celldex Therapeutics, Inc., H1 2014 107
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immunomedics, Inc., H1 2014 108
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2014 109
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Lorus Therapeutics Inc., H1 2014 110
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MEI Pharma, Inc., H1 2014 111
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OXiGENE, Inc., H1 2014 112
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Critical Outcome Technologies Inc., H1 2014 113
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Topotarget A/S, H1 2014 114
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Xenetic Biosciences plc, H1 2014 115
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by JW Pharmaceutical Corporation, H1 2014 116
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Resverlogix Corp., H1 2014 117
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 118
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Synta Pharmaceuticals Corp., H1 2014 119
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioAlliance Pharma SA, H1 2014 120
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sareum Holdings plc, H1 2014 121
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Innate Pharma SA, H1 2014 122
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oscotec Inc., H1 2014 123
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Stem Cell Therapeutics Corp., H1 2014 124
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellerant Therapeutics, Inc., H1 2014 125
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express, Inc., H1 2014 126
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Chroma Therapeutics Ltd., H1 2014 127
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Colby Pharmaceutical Company, H1 2014 128
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ambit Biosciences Corporation, H1 2014 129
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 130
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Philogen S.p.A., H1 2014 131
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oxford BioTherapeutics Ltd, H1 2014 132
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioMAS Ltd., H1 2014 133
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oncodesign SA, H1 2014 134
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ERYtech Pharma, H1 2014 135
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celator Pharmaceuticals, Inc., H1 2014 136
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corporation., H1 2014 137
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascenta Therapeutics, Inc., H1 2014 138
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Coronado Biosciences, Inc., H1 2014 139
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals, Inc., H1 2014 140
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MacroGenics, Inc., H1 2014 141
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arno Therapeutics, Inc., H1 2014 142
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by TetraLogic Pharmaceuticals., H1 2014 143
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Spirogen Ltd., H1 2014 144
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem, H1 2014 145
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Stemline Therapeutics, Inc., H1 2014 146
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories, LLC, H1 2014 147
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onconova Therapeutics, Inc., H1 2014 148
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kainos Medicine, Inc., H1 2014 149
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Syndax Pharmaceuticals, Inc., H1 2014 150
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2014 151
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Esperance Pharmaceuticals, Inc., H1 2014 152
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Trillium Therapeutics Inc., H1 2014 153
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SBI Biotech Co., Ltd., H1 2014 154
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2014 155
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellceutix Corporation, H1 2014 156
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kiadis Pharma B.V., H1 2014 157
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2014 158
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 159
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science, H1 2014 160
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea AB, H1 2014 161
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kinex Pharmaceuticals, LLC, H1 2014 162
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoImmune, Inc., H1 2014 163
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CureTech Ltd., H1 2014 164
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlycoMimetics, Inc., H1 2014 165
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Janssen Biotech, Inc., H1 2014 166
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merus B.V., H1 2014 167
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics B.V., H1 2014 168
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantex Pharmaceuticals, Inc., H1 2014 169
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2014 170
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Interprotein Corporation, H1 2014 171
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EpiZyme, Inc., H1 2014 172
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Targa Therapeutics Corp., H1 2014 173
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NuCana BioMed Limited, H1 2014 174
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sentinel Oncology Limited, H1 2014 175
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 176
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genosco, H1 2014 177
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BerGenBio AS, H1 2014 178
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advancell., H1 2014 179
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Igenica, Inc., H1 2014 180
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Selvita S.A, H1 2014 181
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 182
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreChem, S.L., H1 2014 183
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AROG Pharmaceuticals LLC, H1 2014 184
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 185
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunGene, Inc., H1 2014 186
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Conkwest, Inc., H1 2014 187
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantargia AB, H1 2014 188
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 189
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H1 2014 190
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 191
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc., H1 2014 192
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SpectraMab GmbH, H1 2014 193
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmedartis GmbH, H1 2014 194
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SYNIMMUNE GmbH, H1 2014 195
Assessment by Monotherapy Products, H1 2014 196
Assessment by Combination Products, H1 2014 197
Number of Products by Stage and Target, H1 2014 200
Number of Products by Stage and Mechanism of Action, H1 2014 207
Number of Products by Stage and Route of Administration, H1 2014 215
Number of Products by Stage and Molecule Type, H1 2014 218
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics - Recent Pipeline Updates, H1 2014 605
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H1 2014 828
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H1 2014 830
List of Figures
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2014 35
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H1 2014 36
Number of Products under Development by Companies, H1 2014 37
Number of Products under Investigation by Universities/Institutes, H1 2014 48
Comparative Analysis by Clinical Stage Development, H1 2014 52
Comparative Analysis by Early Stage Products, H1 2014 53
Comparative Analysis by Unknown Stage Development, H1 2014 54
Assessment by Monotherapy Products, H1 2014 196
Assessment by Combination Products, H1 2014 197
Number of Products by Top 10 Target, H1 2014 198
Number of Products by Stage and Top 10 Target, H1 2014 199
Number of Products by Top 10 Mechanism of Action, H1 2014 205
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 206
Number of Products by Top 10 Route of Administration, H1 2014 213
Number of Products by Stage and Top 10 Route of Administration, H1 2014 214
Number of Products by Top 10 Molecule Type, H1 2014 216
Number of Products by Stage and Top 10 Molecule Type, H1 2014 217
